Amuvatinib
Product Sizes
5 mg
£ POA
HY-10206-5MG
100 mg
£ POA
HY-10206-100MG
10 mg
£ POA
HY-10206-10MG
50 mg
£ POA
HY-10206-50MG
10mM/1mL
£ POA
HY-10206-10MM
25 mg
£ POA
HY-10206-25MG
About this Product
- SKU:
- HY-10206
- Additional Names:
- MP470; HPK 56
- CAS Number:
- 850879-09-3
- Extra Details:
- Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit; PDGFRα; Flt3; c-Met and c-Ret. Amuvatinib (MP470) is also a DNA repair suppressor through suppression of DNA repair protein RAD51; thereby disrupting DNA damage repair[1][2][3]. Antineoplastic activity[4].
- Molecular Weight:
- 447.51
- Purity:
- 99.40
- References:
- [1]Choy G, et al. Safety, tolerability, and pharmacokinetics of amuvatinib from three phase 1 clinical studies in healthy volunteers. Cancer Chemother Pharmacol. 2012 Jul;70(1):183-90.|[2]Baxter PA, et al. Plasma and cerebrospinal fluid pharmacokinetics of MP470 in non-human primates. Cancer Chemother Pharmacol. 2011 Apr;67(4):809-12.|[3]Tibes R, et al. A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Feb;71(2):463-71.|[4]David J. Bearss, et al. Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same. US20080226747A1.|[5]Qi W, et al. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. BMC Cancer. 2009 May 11;9:142.
- Research Area:
- Cancer
- Shipping Conditions:
- Ambient
- Storage Conditions:
- -20[o]C; 3 years; 4[o]C; 2 years (Powder)
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
- Pathway:
- Apoptosis;Cell Cycle/DNA Damage;Protein Tyrosine Kinase/RTK
